An Exploratory Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination With Nintedanib (Ofev) in Patients With Idiopathic Pulmonary Fibrosis

Trial Profile

An Exploratory Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination With Nintedanib (Ofev) in Patients With Idiopathic Pulmonary Fibrosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 25 Jun 2018 Results published in the European Respiratory Journal.
    • 23 May 2018 Results assessing safety and tolerability presented at the 114th International Conference of the American Thoracic Society
    • 08 Jun 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top